^
    Back
    Association details:
    Biomarker:CCDC88C-PDGFRB fusion
    Cancer:Lymphoma
    Drug:imatinib (Bcr-abl inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Acta Haematol
    Title:

    Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene

    Excerpt:
    A 2.5-year-old boy was diagnosed with myeloproliferative disorder and eosinophilia associated with lymphoblastic lymphoma both bearing the CCDC88C-PDGFRB fusion. Imatinib therapy resulted in rapid clinical, hematological, and cytogenetic response.
    DOI:
    10.1159/000495687